Navigation Links
Genaera Corporation Elects Paul K. Wotton to Board of Directors
Date:6/30/2008

Wotton. "I look forward to working diligently with Jack and his team to competitively position the Company as a player in the growing metabolic disease market."

About Genaera

Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a phase 1 trial in obesity. In addition, Genaera has a value-driven, fully out-licensed partnership with MedImmune, Inc. for a second core program that is presently undergoing phase 2 clinical testing in asthma. Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value. For further information, please see our website at http://www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding the preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436) and the IL-9 antibody program. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genaera Corporation to Present at BIO Business Forum
2. Genaera Corporation Announces First Quarter Financial Results
3. Genaera Corporation Announces 2007 Financial Results
4. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
5. Genaera Corporation Announces Third Quarter Financial Results
6. Genaera to Present at Biotech 2007 and BIO InvestorForum
7. Genaera Elects New Board Member and Announces Executive Appointments
8. BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use
9. U.S. Commerce Secretary Gutierrez Cuts Ribbon on MaxWell Biocorporations New Pharmaceutical Development Center and Quality Control Laboratory in Ukraine
10. FierceBiotech Names NanoBio Corporation as One of the Fierce 15 Biotech Companies of 2008
11. Allegiance Equity Corporation announces collaboration with Canadian Dairy Commission and Guelph Food Technologies Corporation for Alzheimers and Dementia formulation GG-XT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... MISSION VIEJO, Calif. , Dec. 22, 2014 /PRNewswire/ ... announce that CoPatient, an online medical bill review and ... newest offering in the FREE WellCard Savings discount health ... a medical bill that was more than they expected ... help members reduce health care costs, WellCard Savings is ...
(Date:12/19/2014)... PA (PRWEB) December 19, 2014 ... leading developer and manufacturer of needle-free injection technology, ... agreement with Immunomic Therapeutics, Inc. (“ITI”) for ITI ... device with its LAMP™ vaccine platform. , ... an exclusive Worldwide license to the Biojector®-2000 that ...
(Date:12/19/2014)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today ... privately held company based in Redwood ... big data platform for centralized management and processing ... on-market Genomic Management Solution, Bina-GMS 1 , empowers ... and scalable analyses to maximize the value of ...
(Date:12/19/2014)... Springs, FL (PRWEB) December 18, 2014 ... of the nation’s leading specialty pharmacies, has an ... serve as clinical pharmacy consultants for prescriber offices ... therapy expertise. , “We have a variety ... therapies. For example, those specializing in hepatitis C ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3
... NEW YORK, Oct. 16 Wall St. Network,s 3-Minute,Press ... Tracee Tolentino that,features in-depth interviews with public company executives ... show is designed to provide viewers with insight into ... growth., Shows air Monday through ...
... first-cycle,approval for a new molecular entity (NME) is ... average, according to a new analysis from,PAREXEL Consulting, ... PRXL ),and leading global life sciences consultancy serving ... PAREXEL Consulting,analysis, 60 percent of sales for newly-approved ...
... The future of how the world communicates, and ... from the same source: nanotechnology. According to a ... on Emerging Nanotechnologies (PEN), nanotechnology will be central ... "green" energy technologies. , In the latest ...
Cached Biology Technology:[video] Wall St. Network's 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: IMMU, KYUS 2PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 2PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 3PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 4PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 5
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
(Date:12/10/2014)... SAN DIEGO , Dec. 9, 2014 ... and collaboration catalyst that provides the connective tissue that ... by enabling them to easily share client-level information; earned ... Foundation to expand to organizations serving seniors aging in ... San Diego" partner on December 11 th 4-6p. ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... URBANA The University of Illinois scientists who ... cancer have developed a tool that will help them ... body. And they,ve secured funding from the National Institutes ... carotenoidsthe pigments that give the red, yellow, and orange ...
... the New York Academy of Sciences on December 9 ... science and policy initiatives addressing the global and national ... The Global Obesity Epidemic, is presented by the Academy ... with support from the new Sackler Institute for Nutrition ...
... work in protecting the lives and livelihoods of some of ... national award. At the Times Higher Education awards ceremony ... School of Planning, Architecture and Civil Engineering received the Outstanding ... recognises the team,s work in tackling the world,s worst case ...
Cached Biology News:U of I scientists develop tool to trace metabolism of cancer-fighting tomato compounds 2Super-sized world: Conference addresses global obesity epidemic, explores policies, interventions 2Queen's life-saving research wins education 'Oscar' 2
Protein YIPF6 (YIP1 family member 6). [Source:Uniprot/SWISSPROT;Acc:Q96EC8] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Bovine Calf Serum...
... is designed to deparaffinize and perform Heat ... paraffin-embedded tissue sections mounted on glass microscope ... paraffin at the high temperature used in ... of the paraffin by detergent. Formaldehyde fixation ...
Chicken polyclonal to ytzF ( Abpromise for all tested applications). Antigen: Full length protein...
Biology Products: